Thermo Fisher Scientific reports news across scientific instruments, laboratory equipment, diagnostics consumables, life science reagents and pharmaceutical services. Company updates commonly cover operating results, earnings calls, investor presentations and capital deployment through dividends, share repurchases and acquisitions.
Recurring developments also include collaborations tied to laboratory technologies, proteomics, biobank research, analytical instruments and biopharma customer services. Thermo Fisher’s brand portfolio includes Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD, and its completed Clario acquisition added endpoint data solutions for clinical trials to its Laboratory Products and Biopharma Services segment.
Thermo Fisher Scientific has launched the Renvo Rapid PCR Test, a rapid environmental testing solution for detecting SARS-CoV-2 pathogens in air samples. This test provides results in just 30 minutes, significantly faster than previous 4-24 hour methods. Designed for communal spaces like schools and healthcare facilities, it enhances indoor air monitoring for COVID-19. Utilizing proprietary Oscar PCR technology, this test strengthens risk mitigation efforts in public areas.
Thermo Fisher Scientific (TMO) reported strong financial results for Q4 and full-year 2021. Q4 revenue hit $10.70 billion, with diluted EPS at $4.17 and adjusted EPS at $6.54. For the full year, revenue surged 22% to $39.21 billion, with GAAP EPS increasing 22% to $19.46. The company achieved $9.23 billion in COVID-19 response revenue and invested $2.5 billion to enhance capacity. In acquisitions, TMO deployed $24 billion, including PPD, Inc., and PeproTech, while committing to net-zero carbon emissions by 2050.
Thermo Fisher Scientific (NYSE:TMO) has completed its acquisition of PeproTech for approximately $1.85 billion on December 30, 2021. PeproTech specializes in recombinant proteins such as cytokines and growth factors, which are integral to cell and gene therapy development. This acquisition enhances Thermo Fisher's biosciences portfolio, allowing for improved offerings to pharma and biotech clients. CEO Marc Casper highlighted that the integration will leverage existing capabilities and foster growth in the expanding cell therapy market.
Thermo Fisher Scientific (NYSE: TMO), a leader in scientific services, will have CEO Marc N. Casper present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 8:15 a.m. (EST). The presentation will cover the company's business outlook and future financial expectations. Thermo Fisher reported annual revenues of approximately $40 billion and employs over 100,000 people globally. Investors can access the webcast via the company's website.
Thermo Fisher Scientific (NYSE: TMO) announced the release of its fourth quarter and full year 2021 financial results on February 2, 2022, before market opening. The earnings call will take place at 8:30 a.m. EST on the same day. Investors can listen in via phone or the company's website. Thermo Fisher is a leader in the science sector with annual revenues around $40 billion. The company aims to support customers in various fields, including life sciences and diagnostics, with an extensive range of innovative technologies and services.
Thermo Fisher Scientific (NYSE: TMO), a leader in serving science, announced that Marc N. Casper, its CEO, will present at the 2022 Goldman Healthcare CEOs Unscripted Conference on January 6, 2022, at 9:00 a.m. EDT. This virtual event will highlight the company's initiatives in the healthcare sector. With an annual revenue of approximately $40 billion, Thermo Fisher supports various industries, including life sciences and diagnostics, through its innovative technologies and services. For more details, visit thermofisher.com.
Thermo Fisher Scientific has finalized its acquisition of PPD, Inc. for $17.4 billion, enhancing its position in the biopharma and biotech sectors. The acquisition is expected to add $1.50 to Thermo Fisher's adjusted earnings per share in 2022 and generate approximately $125 million in total synergies within three years. With this integration, Thermo Fisher expands its service offerings across clinical development, covering scientific discovery to drug manufacturing. PPD's stock has ceased trading on Nasdaq as it becomes part of Thermo Fisher's Laboratory Products and Services Segment.
BioGX announced that its SARS-CoV-2 diagnostic portfolio can detect the Omicron variant (B.1.1.529). The surveillance program includes in-silico analyses confirming detection across all variants of interest. BioGX's COVID-19 RT-PCR tests are compatible with several real-time PCR platforms, notably the Xfree COVID-19 Direct RT-PCR, which is FDA authorized for multiple specimen types. This test offers extraction-free options, enhancing workflow efficiency. BioGX operates under ISO 13485 standards, providing over 60 multiplex real-time PCR products worldwide.
Thermo Fisher Scientific (NYSE:TMO) confirmed that its TaqPath COVID-19 tests accurately detect the Omicron variant, ensuring reliable results despite the variant's mutations. The tests, which target three gene regions, remain unaffected in accuracy due to the unaffected orf1a/b and N gene targets. New TaqPath COVID-19 2.0 tests utilize eight gene targets to detect SARS-CoV-2 effectively. This capability is crucial for tracking the Omicron variant's spread and supporting global pandemic response efforts.
Thermo Fisher Scientific (NYSE:TMO) announced its plan to redeem Senior Notes totaling approximately $2.2 billion on December 3, 2021. The redemption includes $1.1 billion of 4.133% Senior Notes due 2025 and $1.1 billion of 4.497% Senior Notes due 2030. Investors will receive the greater of the principal amount or the present value of remaining scheduled payments, plus accrued interest. The company will fund the redemption using cash on hand. This move highlights the firm's commitment to managing its debt effectively.